Browse drugs

…the only without polysorbate). Consequently, desensitisation to tezepelumab was proposed.Results The content of the commercial pen (CP) (21…

…erences (p>0.05).Conclusion and Relevance Patients treated with tezepelumab showed improvements in lung function in both groups, although t…

…kely to meet criteria to be treated with most biologics. Use of Tezepelumab does not require raised eosinophils or FeNO so it may be able t…

…tient decision.Conclusion and Relevance In real-world practice, tezepelumab was effective and tolerated, improving asthma control, reducing…

…enralizumab, dupilumab, mepolizumab, omalizumab, reslizumab and tezepelumab, were estimated using Medicine Carbon Footprint Classifier, a s…

…0) • Mepolizumab 0 (0) • Benralizumab 1 (9) • Dupilumab 1 (9) • Tezepelumab 6 (55) • None 2 (18) Prior biological therapy use n% 0 4 (36) 1…

… 41.9% allergy and atopic dermatitis. Biologics prescribed were omalizumab (61.4%), dupilumab (22.7%), mepolizumab (11.4%), and tezepeluma…

…and nasal polyposis 29.2% (12/41). Biologic therapies used were dupilumab 48.7% (20/41), benralizumab 24.4% (10/41), tezepelumab 12.2% (5…

… in COPD, with up to 11 of 24 respondents (46%) uncertain about Tezepelumab. Perceived challenges to integrating biologics into COPD care i…

…umab n=442, dupilumab n=69, mepolizumab n=146, omalizumab n=51, tezepelumab n=69, not recorded n=29. 49.3% of patients were taking maintena…